Rice Hall James & Associates’s ADMA Biologics ADMA Stock Holding History

Rice Hall James & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.71M	Buy	300,744 +8,809	+3%	+$139K	0.15%	141
2025 Q4	$5.32M	Sell	291,935 -31,718	-10%	-$535K	0.29%	82
2025 Q3	$4.74M	Sell	323,653 -66,962	-17%	-$1.15M	0.26%	93
2025 Q2	$7.11M	Sell	390,615 -18,247	-4%	-$372K	0.38%	67
2025 Q1	$8.11M	Sell	408,862 -2,163	-0.5%	-$37.4K	0.48%	53
2024 Q4	$7.05M	Sell	411,025 -7,011	-2%	-$132K	0.39%	62
2024 Q3	$8.36M	Sell	418,036 -739,219	-64%	-$11.5M	0.45%	59
2024 Q2	$12.9M	Sell	1,157,255 -49,244	-4%	-$413K	0.78%	37
2024 Q1	$7.96M	Buy	+1,206,499	New	+$6.59M	0.45%	57

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Rice Hall James & Associates's ADMA Position: Q1 2026 in Review

Rice Hall James & Associates increased its ADMA Biologics (ADMA) stake by 3% in Q1 2026, buying an estimated $139K and bringing the position to 300,744 shares worth $2.71M. The position accounts for 0.15% of the portfolio, ranked #141.

Rice Hall James & Associates first reported a position in ADMA in Q1 2024 and has held it in 9 quarters since. The position peaked at $12.9M in Q2 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Rice Hall James & Associates held 300,744 shares of ADMA Biologics worth $2.71M as of Q1 2026.
Rice Hall James & Associates bought 8,809 ADMA Biologics shares in Q1 2026, an estimated $139K.
ADMA Biologics made up 0.15% of Rice Hall James & Associates's portfolio in Q1 2026, its #141 holding.
Rice Hall James & Associates first reported a position in ADMA Biologics in Q1 2024 and has held it in 9 quarters since.
Rice Hall James & Associates's ADMA Biologics position peaked at $12.9M in Q2 2024.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.